Power3 Medical Products, Inc (PWRME.OB)
BC-SeraPro� of Power3 Medical Products is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro� test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
Breast cancer is cancer that forms in the cells of the breasts. Breast cancer can occur in both men and women, but it’s far more common in women. After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. But breast cancer rates have fallen in recent years, though doctors aren’t certain why. Still, for many women, breast cancer is the disease they fear most.
Breast cancer can have a number of symptoms but usually shows as a lump or thickening in the breast tissue (although most breast lumps are not cancerous). If cancer is detected at an early stage, it can be treated before it spreads to nearby parts of the body.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro�, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com.
Majestic Gold Corp. (MJS.V)
Of all the minerals mined from the Earth, none is more useful than gold. Its usefulness is derived from a diversity of special properties. Gold conducts electricity, does not tarnish, is very easy to work, can be drawn into wire, can be hammered into thin sheets, alloys with many other metals, can be melted and cast into highly detailed shapes, has a wonderful color and a brilliant luster. Gold is a memorable metal that occupies a special place in the human mind.
Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.
Gold is used as a drug to treat a small number of medical conditions. Injections of weak solutions of sodium aurothiomalate or aurothioglucose are sometimes used to treat rheumatoid arthritis. Particles of a radioactive gold isotope are implanted in tissues to serve as a radiation source in the treatment of certain cancers.
Majestic Gold Corp. announced that Wardrop, A Tetra Tech Company, (”Wardrop”) has completed and delivered a positive Preliminary Assessment (”PA” or “Preliminary Assessment”) for the Songjiagou Gold Project located in Shandong Province, People’s Republic of China.
Highlights are as follows:
– Net Present Value of US $525 million using a 10% discount rate.
– Internal Rate of Return of 78.6%.
– Payback in 1.4 years
– Total gold production of 2.324 million ounces (average 105,645 oz/yr) for life-of-mine
– Life-of-Mine strip ratio 1.87: 1 (waste to ore)
– Mine-Life of 22 years.
The Preliminary Assessment provided by Wardrop has exceeded their expectations and would form the basis for their continued development of the Songjiagou project.
For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net
ULURU Inc. (AMEX:ULU) announced, in compliance with NYSE Amex listing regulations (Company Guide Rule 610(b)), that its audited financial statements for the fiscal year ended December 31, 2010, included in the Company’s Annual Report on Form 10-K, filed on March 31, 2011, contained a going concern qualification from its independent registered auditing firm, Lane Gorman Trubitt, PLLC. This announcement does not represent any change or amendment to the company’s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2010.
ULURU Inc., a pharmaceutical company, engages in the research, development, and commercialization of wound care and muco-adhesive film products in the United States and internationally.
Northgate Minerals Corp. (AMEX:NXG) provided an update on construction activities for its 100% owned Young-Davidson project located beside the town of Matachewan, Ontario, 60 kilometres (”km”) west of Kirkland Lake. The company’s is also pleased to report that follow-up drilling on the YD West zone continues to return positive results. With current proven and probable gold reserves totalling over 2.8 million ounces(1), the Young-Davidson mine is targeting start-up of production in late Q1 2012. The mine is expected to generate an average of 180,000 ounces of gold annually over an initial 15-year mine life.
Northgate Minerals Corporation, together with its subsidiaries, engages in mining, exploring, developing, and processing gold and copper deposits. Its principal producing assets include 100% interests in the Fosterville and Stawell Gold mines in Australia; and the Kemess South mine in Canada.
Sulphco Inc. (AMEX:SUF) announced that it was implementing a substantial reduction in its workforce by April 30, 2011. The employees affected by the workforce reduction are primarily comprised of laboratory support and administrative personnel. In addition, the Company’s Board of Directors has instructed the management team and its advisors to pursue all potential strategic alternatives to obtain value for its shareholders.
SulphCo, Inc., an energy technology company, focuses on the development and commercialization of an oxidative desulfurization (ODS) process for crude oil products, crude oils, natural gasoline, and condensate streams.
No comments:
Post a Comment